Regulation of 2′,5′-oligo(A) synthetase activity in theophylline-treated NIH 3T3 cells  by Itkes, A.V. et al.
Volume 166, number 1 FEBS 1161 January 1984 
Regulation of 2 ’ ,5 ’ -oligo(A) synthetase activity in 
theophylline-treated NIH 3T3 cells 
A.V. Itkes, K.T. Turpaev, O.N. Kartasheva, V.L. Tunitskaya, C.A. Kafiani and E.S. Severin 
Institute of Molecular Biology, Academy of Sciences of the USSR, Moscow 117984, USSR 
Received 14 November 1983 
Sequential treatment of NIH 3T3 cells with theophylline and actinomycin D results in an enhancement of 
2’ ,5 ’ -oligo(A) synthetase activity 2-3-fold exceeding that induced by treatment with theophylline only. 
This ‘superinduction’ phenomenon suggests the existence of a negative control of the enzyme that involves 
a labile, transcription-dependent factor. 
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1, INTRODUCTION 
2’,5’-Oligo(A) synthetase is the enzyme which 
produces an important regulator of cell activity, 
2 ’ ,5 ’ -oligoadenylate, an oligonucleotide that con- 
sists of a few (usually 3 or 4) AMP residues con- 
nected to each other by 2’ ,5 ’ -phosphodiester 
bonds. The main biochemical manner of 
2’,5’-oligo(A) action involves activation of a 
specific latent endoribonuclease (RNse L, RNse F) 
which hydrolyses single stranded RNA [l]. 
2’ ,5 ‘-Oligo(A) synthetase activity is usually found 
in interferon-treated cells, and the antiviral and an- 
tiproliferative effects of interferon are mediated, 
at least partially, by a substantial elevation of 
2’ ,5 ’ -oligo(A) [ 11. An enhancement of the enzyme 
activity was also observed during cell differentia- 
tion [2], regeneration [3], and decrease in the rate 
of cell proliferation [4]. 2 ’ ,5 ’ -Oligo(A) is likely to 
be involved in the regulation of the above 
processes. 
duction of 2’ ,5 ‘-oligo(A) synthetase has begun. 
This procedure is referred to here as a sequential 
treatment with theophylline and actinomycin D. 
2. METHODS 
2.1. Cell culture 
The NIH 3T3 cell line was cultivated in Eagle’s 
medium supplemented with 10% RPM1 1640 
medium and lOolo fetal calf serum. Rapidly grow- 
ing cells (2 24 h before confluence) were used in 
our experiments. 
The cells were treated with theophylline (2 mM) 
followed by actinomycin D (1 pg/ml) where 
indicated. 
2.2. 2 ‘,5 ‘-Oligo(A) synthetase assay 
We have shown [5-71 that an elevation of 
2 ’ ,5 ’ -oligo(A) synthetase activity follows a rise in 
the intracellular CAMP level induced by different 
agents including theophylline, a specific inhibitor 
of the CAMP phosphodiesterase (PDE). We show 
here that an additional, 2-3-fold increase in en- 
zyme activity is observed if actinomycin D is added 
to the culture, when the theophylline-dependent in- 
The cells were detached with Versen solution, 
collected by centrifugation and resuspended in 30 
mM KCl, 5 mM MgClz, 1 mM dithiothreitol, 10% 
glycerol, 0.05% Triton X-100, 20 mM Tris-HCI 
(pH 8.0). The cell suspension was incubated for 30 
min at 4°C then centrifuged for 6 min at 8000 x 
g, the supernatant being used to obtain a protein 
fraction lacking 2’-phosphodiesterase activity, and 
the 2 ’ ,5 ’ -oligo(A) synthetase was assayed as in [5]. 
2.3. CAMP assay 
The CAMP level was assayed as in [5]. 
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3. RESULTS AND DISCUSSION 
3.1. CAMP level in the cells sequentially treated 
with theophylline and actinomycin D 
After theophylline addition to the culture 
medium, a transient 2.5fold elevation of the in- 
tracellular CAMP level was observed. In about 8 h, 
CAMP decreased to the initial level and remained 
constant for at least 16 h (fig.1). 
A second increase in the CAMP level was observ- 
ed when the theophylline-containing medium was 
replaced (after 10 h incubation) by the actinomycin 
D-containing medium (fig.1). This second CAMP 
elevation could be due to inhibition of synthesis of 
mRNA for inducible CAMP PDE. It is known that 
CAMP PDE can be induced by high concentrations 
of CAMP [8]. In our case, the cells exposed to ac- 
tinomycin D were pretreated with theophylline 
which induced CAMP enhancement. Hence CAMP- 
dependent induction of CAMP PDE might be ex- 
pected. Actinomycin D inhibition of the synthesis 
of mRNA for labile inducible CAMP PDE would 
result in a fall in the total CAMP PDE activity and, 
consequently, in a rise in CAMP level. 
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Fig. 1. CAMP level in NIH 3T3 cells treated with 
theophylline (0) or with theophylline and actinomycin 
D sequentially (0). The theophylline-containing 
medium was replaced by actinomycin D-containing 
medium 10 h after theophylline addition. The CAMP 
level in untreated cells remained at the initial level for at 
least 24 h. Values are means (+ SE) of 4 independent 
measurements. 
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Fig. 2. 2’,5’-Oligo(A) synthetase activity in NIH 3T3 
cells treated with theophylline (0) or with theophylline 
and actinomycin D sequentially (0). The theophylline- 
containing medium was replaced by actinomycin D- 
containing medium 10 h after theophylline addition. En- 
zyme activity is expressed as pmol AMP incorporated in- 
to the fraction of 2’,5’-oligo(A) trimer/l h per mg pro- 
tein of the lysate fraction lacking 2’-phosphodiesterase 
activity (see section 2). Enzyme activity in untreated cells 
and in cells treated with actinomycin D did not vary 
from the initial level more than 40% during at least 24 
h. Values are means (*SE) of 4 independent 
measurements. 
This is surely one of the possible explanations 
for the two-phase CAMP increases observed; direct 
experiments are necessary to test this proposal. 
3.2. 2 ‘,5 ‘-Oligo(A) synthetase activity in the cells 
sequentially treated with theophylline and 
actinomycin D 
Treatment of cells with theophylline (or with 
other agents that cause CAMP elevation) results in 
2’ ,5 ’ -oligo(A) synthetase induction 15-71. Fig. 2 
demonstrates a 2.5-fold increase in the enzyme 
level caused by 2 mM theophylline (the concentra- 
tion used in our experiments). The rise in enzyme 
activity began about 8 h after theophylline addi- 
tion and had attained a maximal level by 12 h. 
Sequential treatment of the cells with 
theophylline and actinomycin D (10 h incubation 
with theophylline and subsequent change of the 
medium and incubation with actinomycin D) 
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resulted in a more prolonged enhancement of the 
2 ’ ,5 ’ -oligo(A) synthetase activity; 24 h after 
theophylline addition (i.e. in 14 h after ac- 
tinomycin D addition) the activity was S-fold 
higher compared to the initial level (fig.2). 
The rate of enzyme activity enhancement 
depended on the time of incubation of the cells 
with both agents; maximal activity was attained 
after 10 h incubation with theophylline followed 
by the change of the medium and incubation with 
actinomycin D for 14 h (table 1). 
The second rise in CAMP level observed with ac- 
tinomycin D could not induce 2 ’ ,5 ’ -oligo(A) syn- 
thetase because actinomycin D prevents mRNA 
synthesis. Indeed, theophylline and actinomycin 
D, added simultaneously to the medium, caused a 
rise in CAMP level similar to that induced by 
theophylline only, but no enhancement of 
2’ ,5 ’ -oligo(A) synthetase activity occurred during 
at least 24 h (not shown), The CAMP-dependent in- 
duction of the enzyme caused by adrenaline treat- 
ment of the cells was also prevented by actino- 
mycin D [7]. 
Nevertheless, the sequential (but not 
simultaneous) treatment of the cells with 
theophylline and actinomycin D resulted in a rise 
in the 2’ ,5 ’ -oligo(A) synthetase level that was 
2-3-fold higher than that caused by treatment with 
Table 1 
2’ ,S’-Oligo(A) synthetase activity in NIH 3T3 cells se- 
quentially treated with theophylline and actinomycin D 
Time of Time of Relative 
incubation with incubation with activity of 
theophylline actinomycin D 2 ’ ,5 ’ -oligo(A) 
(h) (h) synthetase 
0 0 1.0 + 0.2 
0 24 0.9 f 0.3 
24 0 1.7 f 0.3 
16 8 2.8 + 1.0 
14 10 4.9 + 1.5 
12 12 4.1 * 1.5 
Cells were sequentially treated with theophylline and ac- 
tinomycin D (see section 2); 2’ ,5 ‘-oligo(A) synthetase 
was assayed 24 h after theophylline addition except in 
control where the assay was carried out with untreated 
cells (row 1) or actinomycin D-treated cells 24 h after the 
addition of the antibiotic (row 2). Values are means 
( + SE) of 4 independent experiments 
theophylline only (fig.2). 
These data suggest that at late stages of the 
theophylline-dependent induction of 2 ’ ,5 ’ -oli- 
go(A) synthetase, prevention of further enhance- 
ment of the enzyme level requires RNA synthesis. 
Inhibition of RNA synthesis by actinomycin D 
results in a more prolonged rise in the enzyme ac- 
tivity, the so-called ‘superinduction’. 
The molecular mechanism of this process is not 
clear, and further experiments are necessary to 
draw any conclusions. It should be noted, 
however, that similar ‘superinduction’ of 
2’,5’-oligo(A) synthetase has been observed upon 
sequential treatment of chicken embryonic 
fibroblasts with interferon and cycloheximide [9]. 
The authors have supposed that the phenomenon 
involves a hypothetical ‘labile protein agent’ which 
inactivates mRNA for 2’,5’-oligo(A) synthetase: 
when synthesis of this labile protein was inhibited 
by cycloheximide, enzyme ‘superinduction’ occur- 
red [9]. Our data agree with this hypothesis: in our 
experiments, the synthesis of the labile protein 
agent was supposedly inhibited by actinomycin D. 
In addition, these data suggest that the 
mechanisms of cellular regulation of interferon- 
induced and CAMP-induced 2 ’ ,5 ’ -oligo(A) syn- 
thetase are similar. 
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